YIFAN PHARMACEUTICAL(SZ:002019) Quan Jing Wang·2026-01-05 12:36Core Viewpoint - Yifan Pharmaceutical has signed an exclusive agreement for the commercialization of ACT001, a first-in-class drug developed by Shangde Yaoyuan, targeting small cell lung cancer brain metastases, marking a significant step in the company's innovation and internationalization strategy [1][2]. Group 1: Agreement Details - Yifan Pharmaceutical's subsidiary, Yifan Pharmaceutical Co., will pay a total of 100 million yuan as an upfront payment, with options for either a cornerstone investment of 100 million yuan or a milestone payment of 50 million yuan, along with a tiered revenue-sharing model [1]. - The agreement covers exclusive commercialization rights in mainland China and surrounding regions, including South Korea and Southeast Asia, leveraging Yifan's existing registration and sales network in Southeast Asia [3]. Group 2: Product and Market Potential - ACT001 has received "breakthrough therapy" designation from the National Medical Products Administration and is currently in Phase III clinical trials, showing significant clinical advantages by enhancing the efficacy of chemotherapy and immunotherapy [2]. - The drug addresses a critical clinical need in the treatment of small cell lung cancer brain metastases, where existing treatment options are limited, potentially leading to improved patient outcomes [2][3]. Group 3: Strategic Implications - This collaboration is seen as a practical step for Yifan Pharmaceutical to integrate innovative products into its portfolio, enhancing its capabilities in research, production, registration, and sales [2]. - While the transaction may increase short-term expenditures, successful commercialization of ACT001 is expected to contribute to sustainable business growth and performance in the long run [3].